Oncotarget最新文献

{"title":"Correction: Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.","authors":"Claudia Fumarola, Daniele Cretella, Silvia La Monica, Mara A Bonelli, Roberta Alfieri, Cristina Caffarra, Federico Quaini, Denise Madeddu, Angela Falco, Andrea Cavazzoni, Graziana Digiacomo, Giulia Mazzaschi, Valentina Vivo, Elisabetta Barocelli, Marcello Tiseo, Pier Giorgio Petronini, Andrea Ardizzoni","doi":"10.18632/oncotarget.28844","DOIUrl":"10.18632/oncotarget.28844","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"76-77"},"PeriodicalIF":0.0,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Bisphenol A induces cell cycle arrest in primary and prostate cancer cells through EGFR/ERK/p53 signaling pathway activation.","authors":"Antonio Bilancio, Paola Bontempo, Marzia Di Donato, Mariarosaria Conte, Pia Giovannelli, Lucia Altucci, Antimo Migliaccio, Gabriella Castoria","doi":"10.18632/oncotarget.28845","DOIUrl":"10.18632/oncotarget.28845","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"74-75"},"PeriodicalIF":0.0,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.","authors":"Michael R Booth, Laurence Booth, Jane L Roberts, John M Kirkwood, Paul Dent","doi":"10.18632/oncotarget.28861","DOIUrl":"10.18632/oncotarget.28861","url":null,"abstract":"<p><p>Copyright: &copy; 2026 Booth et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Mechanisms by which the Stearoyl-CoA desaturase (SCD1) inhibitor aramchol kills tumor cells have recently been described, demonstrating that enhanced signaling through the AMPK played a key role in the processes regulating cell death. Metformin is an anti-hyperglycemic drug which utilizes AMPK signaling to reduce plasma glucose levels. The primary site of metastatic spread of uveal melanoma (UM) is the liver and aramchol concentrates in the liver compared to plasma and other tissues. Aramchol and metformin interacted to modestly enhance cell death in PDX UM cells, though this was less than that caused by the combination of aramchol and the multi-kinase inhibitor regorafenib. Metformin significantly enhanced killing by aramchol plus regorafenib. Metformin significantly enhanced autophagosome formation and autophagic flux caused by aramchol plus regorafenib. Knock down of Beclin1, ATG5 or LAMP2 reduced autophagosome and autolysosome formation, and tumor cell killing. Knock down of BID further enhanced the protective effect of Beclin1 knock down. Knock down of SCD1 enhanced the percentage of dead cells in vehicle control treated cells but did not alter the abilities of drugs to kill tumor cells. Our data demonstrates that UM cells are killed by treatment with aramchol plus regorafenib plus metformin via enhanced autophagic flux and that this combination may have the potential to control UM tumors that have metastasized to the liver.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"78-89"},"PeriodicalIF":0.0,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer.","authors":"Allison Makovec, John T Phoenix, Hannah E Bergom, Ella Boytim, Ava P Gustafson, Aiden Deacon, Sydney Tape, Atef Ali, Megan Ludwig, Samuel P Pitzen, David Moline, Camden Richter, Hudson Longie, Mei-Chi Su, Sampreeti Jena, Pornlada Likasitwatanakul, Justin M Drake, R Stephanie Huang, William C Hahn, Jonathan P Rennhack, Scott M Dehm, Steven Kregel, Emmanuel S Antonarakis, Justin Hwang","doi":"10.18632/oncotarget.28826","DOIUrl":"10.18632/oncotarget.28826","url":null,"abstract":"<p><p>Copyright: &copy; 2026 Makovec et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Prostate gland cells can be transcriptionally and morphologically characterized as basal and luminal. About 30&#x2013;40% of advanced prostate cancers (PC) harbor basal-like transcription programs. In castration-resistant PC (CRPC), studies indicate that basal and stem cell-like (SCL) tumors are major resistance mechanisms to androgen receptor (AR)-targeted therapies. SCL tumors have reduced AR activity and increased stem-cell activity that promotes tumor formation, which contributes to poor clinical outcomes. We determined that CREB5 is a key regulator of basal and SCL transcriptional programs and tumor-forming phenotypes in PC. Through in silico modeling of PC transcriptomes and several pre-defined PC signaling programs, CREB5 expression was best associated with basal-like gene signatures and SCL-associated genes in primary PC and CRPCs (n = 493 and 208). This included associations with FOSL1 and other AP-1 transcription factors. We further found that CREB5 interacted with AP-1 proteins and bound to the regulatory elements of AP-1 genes, suggesting a mechanistic role in regulating the activity of AP-1 genes. In AR-positive cells, CREB5 overexpression promoted cell colony growth with tumorigenic properties and increased tumor size in vivo. These findings implicate CREB5 as a driver of the transcriptional programs underlying AR-independent basal and SCL CRPC subtypes, and this activity is detectable in primary PC.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"59-73"},"PeriodicalIF":0.0,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.","authors":"Uzma Saqib, Monika Pandey, Krishnan Hajela","doi":"10.18632/oncotarget.28836","DOIUrl":"10.18632/oncotarget.28836","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"54-56"},"PeriodicalIF":0.0,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells.","authors":"Steven A Greenberg","doi":"10.18632/oncotarget.28846","DOIUrl":"10.18632/oncotarget.28846","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"57-58"},"PeriodicalIF":0.0,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12935076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Censorship in science: How publishing decisions could have shaped the perceived \"general consensus\" on COVID-19 vaccine safety and efficacy.","authors":"Panagis Polykretis, Janci C Lindsay, Patrizia Gentilini, Nafuko Konishi, Masanori Fukushima","doi":"10.18632/oncotarget.28829","DOIUrl":"10.18632/oncotarget.28829","url":null,"abstract":"<p><p>Copyright: &copy; 2026 Polykretis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"50-53"},"PeriodicalIF":0.0,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12935075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms.","authors":"Patrizia Gentilini, Janci C Lindsay, Nafuko Konishi, Masanori Fukushima, Panagis Polykretis","doi":"10.18632/oncotarget.28827","DOIUrl":"10.18632/oncotarget.28827","url":null,"abstract":"<p><p>Copyright: &copy; 2026 Gentilini et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This article investigates the potential association between modified mRNA (modRNA) COVID-19 vaccinations and the development of haematopoietic cancers. We present a case involving a healthy, young, athletic woman who developed acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) following her second dose of the Pfizer/BioNTech COVID-19 vaccine (Comirnaty&#x00AE;). This case is part of an expanding body of literature documenting similar occurrences after modRNA vaccinations, which we critically examine. Emerging evidence suggests that the biodistribution and persistence of modRNA, facilitated by lipid nanoparticles, can affect various tissues and organs, including the bone marrow and other blood-forming organs. Notably, modRNA vaccines exhibit a particular affinity for the bone marrow, potentially influencing the immune system at multiple levels and triggering both autoimmune disorders and neoplastic processes. In this article, we assess the risk of developing haematopoietic cancers post-modRNA vaccination based on current scientific literature and explore the reported potential genetic and molecular mechanisms involved in disease pathogenesis. By integrating clinical observations and current research, we aim to provide valuable insights into the potential carcinogenic outcomes associated with modRNA vaccination.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"34-49"},"PeriodicalIF":0.0,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12935077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Methylation-mediated silencing of microRNA-211 promotes cell growth and epithelial to mesenchymal transition through activation of the AKT/β-catenin pathway in GBM.","authors":"Weidong Li, Xiaobo Miao, Lingling Liu, Yue Zhang, Xuejun Jin, Xiaojun Luo, Hai Gao, Xubin Deng","doi":"10.18632/oncotarget.28840","DOIUrl":"https://doi.org/10.18632/oncotarget.28840","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13112244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: microRNA526b servers as a prognostic factor and exhibits tumor suppressive property by targeting Sirtuin 7 in hepatocellular carcinoma.","authors":"Xin Liu, Liu Yang, Jianfeng Tu, Wenwei Cai, Meiqi Zhang, Zhangxuan Shou, Yingmin Yao, Qiuran Xu","doi":"10.18632/oncotarget.28869","DOIUrl":"https://doi.org/10.18632/oncotarget.28869","url":null,"abstract":"","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"17 1","pages":"195-196"},"PeriodicalIF":0.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13112270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}